Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFβ and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2

Clinical Immunology

Volumn 95, Issue 3, 2000, Pages 182-189

  Gorczynski, R M ^a   Bransom, J ^b   Cattral, M ^a   Huang, X ^a   Lei, J ^a   Xiaorong, L ^a   Min, W P ^a   Wan, Y ^b   Gauldie, J ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Cytokines; Dendritic cells; Immunoregulation; OX 2; Transplantation

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MITOMYCIN C; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GENE EXPRESSION REGULATION; GRAFT SURVIVAL; IMMUNOREGULATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0034117099     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4860     Document Type: Article

References (44)

1. Akolkar P. N., Gulwani-Akolkar B., Pergolizzi R., Bigler R. D., Silver J. Influence of HLA genes on T cell receptor V segment frequencies and expression levels in peripheral blood lymphocytes. J. Immunol. 150:1993;2761-2773.
2. Ahvazi B. C., Jacobs P., Stevenson M. M. Role of macrophage-derived nitric oxide in suppression of lymphocyte proliferation during blood-stage malaria. J. Leukocyte Biol. 58:1995;23-31.
3. Albina J. E., Abate J. A., Henry W. L. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. J. Immunol. 147:1991;144-152.
4. Qian J. H., Hashimoto T., Fujiwara H., Hamaoka T. Studies on the induction of tolerance to alloanatigens. J. Immunol. 134:1985;3656-3663.
5. Kenick S., Lowry R. P., Forbes R. D. S., Lisbona R. Prolonged cardiac allograft survival following portal venous inoculation of allogeneic cells: What is "hepatic tolerance? Transplant. Proc. 19:1987;478-480.
6. Gorczynski R. M. Immunosuppression induced by hepatic portal venous immunization spares reactivity in IL-4 producing T lymphocytes. Immunol. Lett. 33:1992;67-77.
7. Thelen M., Wirthmueller U. Phospholipases and protein kinases during phagocytic activation. Curr. Opin. Immunol. 6:1994;106-112.
8. Gorczynski R. M., Cohen Z., Leung Y., Chen Z. Gamma delta TCR (+) hybridomas derived from mice preimmunized via the portal vein adoptively transfer increased skin allograft survival in vivo. J. Immunol. 157:1996;574-581.
9. Gorczynski R. M., Cohen Z., Fu X. M., Hua Z., Sun Y. L., Chen Z. Q. Interleukin-13, in combination with anti interleukin-12, increases graft prolongation after portal venous immunization with cultured allogeneic bone marrow-derived dendritic cells. Transplantation. 62:1996;1592-1600.
10. Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
11. Salomon B., Cohen J. L., Masurier C., Klatzmann D. Three populations of mouse Lymph node dendritic cells with different origins and dynamics. J. Immunol. 160:1998;708-717.
12. Leenen P. J. M., Radosevic K., Voerman J. S. A., Salomon B., vanRooijen N., Klatzmann D., vanEwijk W. Heterogeneity of mouse spleen dendritic cells: In vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J. Immunol. 160:1998;2166-2173.
13. Kronin V., Winkel K., Suss G., Kelso A., Heath W., Kirberg J., vonBoehmer H., Shortman K. Subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J. Immunol. 157:1996;3819-3827.
14. Suss G., Shortman K. A subclass of dendritic cells kills CD4+ T cells via Fas/Fas-ligand-induced aoptosis. J. Exp. Med. 183:1996;1789-1796.
15. Gorczynski L., Chen Z., Hu J., Kai G., Ramakrishna V., Gorczynski R. M. Evidence that an OX-2 positive cell can inhibit the stimulation of type-1 cytokine production by bone-marrow-derived B7-1 (and B7-2) positive dendritic cells. J. Immunol. 162:1999;774-781.
16. Amigorena S. Antigen presentation by dendritic cells. M. S. Med. Sci. 15:1999;931-938.
17. Niimi M., Pearson T. C., Larsen C. P., Alexander D. Z., Hollenbaugh D., Aruffo A., Linsley P. S., Thomas E., Campbell K., Fanslow W. C., Geha R. S., Morris P. J., Wood K. J. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J. Immunol. 161:1998;5331-5337.
18. Min W. P., Gorczynski R. M., Huang X. Y., Kushida M., Kim P., Obataki M., Lei J., Suri R. M., Cattral M. S. Dendritic cells genetically engineered to express Fas Ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164:2000;000-009.
19. George J. F., Sweeney S. D., Kirklin J. K., Simpson E. M., Goldstein D. R., Thomas J. M. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nature Med. 4:1998;333-335.
20. Griffith T. S., Yu X. H., Herndon J. M., Green D. R., Ferguson T. A. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 5:1996;7-16.
21. Korbutt G. S., Elliott J. F., Rajotte R. V. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes. 46:1997;317-322.
22. Lee W. C., Zhong C., Qian S., Wan Y., Gauldie J., Mi Z., Robbins P. D., Thomson A. W., Lu L. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGFb. Transplantation. 66:1998;1810-1817.
23. Ragheb R., Abrahams S., Beecroft R., Hu J., Ni J., Ramakrishna V., Yu G., Gorczynski R. M. Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2. Immunol. Lett. 68:1999;311-315.
24. Gorczynski R. M., Chen Z., Chung S., Cohen Z., Levy G., Sullivan B., Fu X.-M. Prolongation of rat small bowel or renal allograft survival by pretransplant transfusion and/or by varying the route of allograft venous drainage. Transplantation. 58:1994;816-820.
25. Gorczynski R. M. Regulation of IFNg and IL-10 synthesis in vivo, as well as continuous antigen exposure, is associated with tolerance to murine skin allografts. Cell. Immunol. 160:1995;224-231.
26. Bett A. J., Haddara W., Prevec L., Graham F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA. 91:1994;8802-8806.
27. Gorczynski R. M., Wojcik D. A role for non-specific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1 and interleukin-10) immunomodulation in the prolongation of skin allografts after antigen-specific pre-transplant immunization or transfusion. J. Immunol. 152:1994;2011-2019.
28. Gorczynski R. M., Chen Z., Fu X. M., Zeng H. Increased expression of the novel molecule Ox-2 is involved in prolongation of murine renal allograft survival. Transplantation. 65:1998;1106-1114.
29. Gorczynski R. M., Cohen Z., Fu X. M., Lei J. Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization. Transplant. Proc. 31:1999;577-578.
30. Gorczynski R. M., Cattral M. S., Chen Z. G., Hu J. A., Lei J., Min W. P., Yu G., Ni J. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J. Immunol. 163:1999;1654-1660.
31. Austyn J. M. Dendritic cells. Curr. Opin. Hematol. 5:1998;3-15.
32. Steinman R. M., Pack M., Inaba K. Dendritic cell development and maturation. Adv. Exp. Med. Biol. 417:1997;1-6.
33. Zhang H., Xu X., Liu D., Liu W. M., Yang P., Wang Z., Edwards C. K., Bluethmann H., Mountz J. D., Zhou T. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162:1999;1423-1430.
34. Porgador A., Irvine K. R., Iwasaki A., Barber B. H., Restifo N. P., Germain R. N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8(+)T cells after gene gun immunization. J. Exp. Med. 188:1998;1075-1082.
35. Song E. S., Lee V., Surh C. D., Lynn A., Brumm D., Jolly D. J., Warner J. F., Chada S. Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 94:1997;1943-1948.
36. Wan Y. H., Emtage P., Foley R., Carter R., Gauldie J. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int. J. Oncol. 14:1999;771-776.
37. McArthur J. G., Mulligan R. C. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21:1998;41-47.
38. Ahuja S. S., Mummidid S., Malech H. L., Ahuja S. K. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12. J. Immunol. 161:1998;868-876.
39. Takayama T., Nishioka Y., Lu L., Lotze M. T., Tahara H., Thomson A. W. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation. 66:1998;1567-1574.
40. Sonderbye L. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction. Exp. Clin. Immunogenet. 15:1998;100-111.
41. Zhang H. G., Liu D., Heike Y., Yang P. A., Wang Z., Wang X. Y., Curiel D. T., Zhou T., Mountz J. D. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 16:1998;1045-1049.
42. Gorczynski R. M., Hozumi N., Wolfe S. W., Chen Z. Interleukin-12, in combination with anti-interleukin-10, reverses graft prolongation after portal venous immunization. Transplantation. 60:1995;1337-1341.
43. Krieger N. R., Yuh D., McIntyre W. B., Flavin T. F., Yin D. P., Robbins R., Fathman C. G. Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. J. Surg. Res. 76:1998;174-178.
44. Zheng X. X., Markees T. G., Hancock W. W., Li Y. S., Greiner D. L., Li X. C., Mordes J. P., Sayegh M. H., Rossini A. A., Strom T. B. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J. Immunol. 162:1999;4983-4990.